Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

A photography exhibition of secondary breast cancer patients is aiming to raise awareness of the signs of metastasis. Photographer Abigail Fahey, from Worthing in West Sussex, has captured images ...

Receiving radiation therapy for breast cancers harboring TP53 germline variants may cause secondary cancers, but risk estimates are unconfirmed. Patients with breast cancer who carry TP53 germline ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

But neighbourhood secondary schools, some of which are quite young, are getting in on the act too and are finding new ways to build and expand these volunteer networks with the hope that it will ...

Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa continue to perform ... based on alpha-emitting isotopes for rare cancers. We will keep you updated as we continue to access ...

Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements ...